Legal Representation
Attorney
ARLENE D HANKS
USPTO Deadlines
Next Deadline
1291 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2023-05-16)
Due Date
May 16, 2029
Grace Period Ends
November 16, 2029
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
26 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| May 24, 2023 | OP.T | T | OPPOSITION TERMINATED NO. 999999 | Loading... |
| May 24, 2023 | OP.D | T | OPPOSITION DISMISSED NO. 999999 | Loading... |
| May 16, 2023 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| May 16, 2023 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Apr 12, 2023 | SUNA | E | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | Loading... |
| Apr 11, 2023 | CNPR | P | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | Loading... |
| Mar 25, 2023 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE | Loading... |
| Mar 24, 2023 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Mar 10, 2023 | IUAF | S | USE AMENDMENT FILED | Loading... |
| Mar 10, 2023 | EISU | I | TEAS STATEMENT OF USE RECEIVED | Loading... |
| Sep 13, 2022 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Jun 5, 2020 | OP.I | T | OPPOSITION INSTITUTED NO. 999999 | Loading... |
| May 6, 2020 | ETOF | T | EXTENSION OF TIME TO OPPOSE RECEIVED | Loading... |
| Apr 7, 2020 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Apr 7, 2020 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Mar 18, 2020 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Mar 5, 2020 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Feb 27, 2020 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| Feb 27, 2020 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| Feb 27, 2020 | GNEA | F | EXAMINERS AMENDMENT E-MAILED | Loading... |
| Feb 27, 2020 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Feb 27, 2020 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| Feb 21, 2020 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Nov 26, 2019 | MDSM | E | NOTICE OF DESIGN SEARCH CODE E-MAILED | Loading... |
| Nov 23, 2019 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Nov 21, 2019 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 035
Site management organization services, namely, business assistance services for other clinical research organizations, namely, new trial and study procurement, budgeting and contracting, business study feasibilities, creation and implementation of standard operating procedures, providing and managing study coordinators; development of comprehensive patient recruitment strategies; overseeing informed consent administration and management, namely, business administration and business management assistance for others; patient referral management, namely, business administration and business management assistance for others; business consulting and management in the field of clinical trials, namely, clinical data and regulatory submission management on behalf of medical, biopharmaceutical and biotechnology companies to assist them with clinical research, clinical trials, applications for drug approval and late phase and/or real world research studies; business data compilation and tracking services for others, namely, interactive tracking of clinical trial subject enrollment, status and adverse side effects of treatment and medication, including interactive services on mobile platform; business consulting services, namely, consulting regarding regulatory inspections and biopharmaceutical and biotechnology audits
First Use Anywhere:
20200200
First Use in Commerce:
20200200
Class 042
Medical and scientific research, namely, conducting clinical trials and translational research for others; clinical research services during clinical trials of pharmaceuticals and medical devices, namely, data collection service using software to evaluate, analyze, and collect clinical data; multitherapeutic site management organization services, namely, research and development services in the field of pharmaceuticals and drug development
First Use Anywhere:
20200200
First Use in Commerce:
20200200
Additional Information
Design Mark
The mark consists of the term "AVACARE" in stylized letters, beginning with a capital letter "A" in which the horizontal element of the letter is formed from left to right by three circles of increasing size, a slightly larger oval, and a short line that becomes the top of the following lower case letter "V" in the following lowercase letter string "VACARE," which appears above the terms "CLINICAL RESEARCH NETWORK" centered thereunder in smaller uppercase font, all of which elements are in the color seafoam green.
Color Claim
The color(s) seafoam green is/are claimed as a feature of the mark.
Pseudo Mark
AVACARE CLINICAL RESEARCH NETWORK
Classification
International Classes
035
042
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"CLINICAL RESEARCH NETWORK"